Walleye Capital LLC Acquires Shares of 80,910 SiBone $SIBN

Key Points

• Walleye Capital LLC acquired a new stake in SiBone, purchasing 80,910 shares valued at approximately $1,135,000, representing about 0.19% ownership.
• Several institutional investors have increased their holdings in SiBone, with notable increases from Wells Fargo and Dimensional Fund Advisors, demonstrating significant interest in the company.
• Analysts largely maintain a "buy" rating for SiBone, with average price targets ranging from $22.00 to $25.00, indicating positive sentiment despite recent insider selling activities.

Walleye Capital LLC acquired a new position in shares of SiBone (NASDAQ:SIBN - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 80,910 shares of the company's stock, valued at approximately $1,135,000. Walleye Capital LLC owned approximately 0.19% of SiBone at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SIBN. Wells Fargo & Company MN boosted its holdings in SiBone by 36.3% during the fourth quarter. Wells Fargo & Company MN now owns 20,724 shares of the company's stock worth $291,000 after buying an additional 5,519 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of SiBone by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after purchasing an additional 1,413 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of SiBone in the fourth quarter valued at about $1,233,000. Barclays PLC lifted its holdings in shares of SiBone by 2.7% in the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after purchasing an additional 2,589 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of SiBone by 10.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 354,835 shares of the company's stock valued at $4,974,000 after purchasing an additional 34,512 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company's stock.

Insider Buying and Selling at SiBone

In related news, Director John Gordon Freund sold 12,132 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $15.99, for a total transaction of $193,990.68. Following the completion of the sale, the director directly owned 91,767 shares of the company's stock, valued at $1,467,354.33. This represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laura Francis sold 11,343 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.60, for a total transaction of $176,950.80. Following the sale, the chief executive officer owned 419,704 shares in the company, valued at $6,547,382.40. This represents a 2.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 46,590 shares of company stock valued at $765,137. Corporate insiders own 4.00% of the company's stock.

SiBone Stock Performance

SiBone stock traded up $0.04 during midday trading on Friday, reaching $16.39. 39,942 shares of the stock traded hands, compared to its average volume of 421,376. The firm has a fifty day moving average price of $16.92 and a two-hundred day moving average price of $16.51. The firm has a market cap of $706.89 million, a price-to-earnings ratio of -29.27 and a beta of 0.81. SiBone has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The company has a current ratio of 8.38, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The company had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that SiBone will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

SIBN has been the topic of several recent research reports. Wall Street Zen downgraded shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an "overweight" rating in a research report on Monday, August 11th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, SiBone presently has a consensus rating of "Buy" and a consensus price target of $23.67.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.